
8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...
The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...
Mats Blom
![]()
Mats Blom has a BA in Business Administration and Economics from the University of Lund followed by an MBA from I:E:S:E University of Navarra, Barcelona. Mr. Blom has several years experience as a management consultant at Gemini Consulting and at Ernst&Youngs Transaction Services division. Mr Blom has held CFO positions at Active Biotech and Anoto both publicly listed on the Nasdaq OMX in Stockholm. Before joining Zealand Pharma A/S March 1st, 2010 Mr. Blom served as Chief Financial Officer at Swedish Orphan International a leading European orphan drug company recently acquired by BioVitrum of Sweden.
Phone: +45 4328 1240
e-mail: mabl@zp.dk
Fill in the form below to tip a friend about this page.
When this page is updated you will be updated by e-mail.
Home Legal Disclaimer Updated: 27.7.2010